Altium Capital Management LP Immatics N.V. Transaction History

Altium Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$6.64 - $12.85 $3.12 Million - $6.04 Million	-469,980 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$10.81 - $14.38 $97,365 - $129,520	-9,007 Reduced 1.88%	469,980 $6.32 Million
Q3 2021 Nov 17, 2021	BUY	$11.58 - $15.46 $104,069 - $138,939	8,987 Added 1.91%	478,987 $6.23 Million
Q3 2021 Nov 15, 2021	BUY	$11.58 - $15.46 $1.45 Million - $1.94 Million	125,442 Added 36.41%	470,000 $6.03 Million
Q1 2021 May 06, 2021	SELL	$10.24 - $14.6 $625,786 - $892,235	-61,112 Reduced 15.06%	344,558 $3.86 Million
Q4 2020 May 05, 2021	BUY	$9.67 - $12.05 $3.92 Million - $4.89 Million	405,670 New	405,670 $4.38 Million

76.6M

571K

210K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.